



February 18 2016

Company name	3 - D	M a t r i x ,	L t d .
A d d r e s s	3-2-4 Kojimachi, Chiyoda-ku, Tokyo		
P r e s i d e n t	Kentarō Takamura		
C o d e N u m b e r	7777		
C o n t a c t	Director	Tomoyuki Arai	
T E L	+81 3 (3511)3440		

Partnership Agreement concluded with Genelife S.A regarding sales and marketing of absorbable local hemostat “PuraStat®” in Mexico

Our consolidated subsidiary in Europe, 3-D Matrix Europe SAS. (“3DMEU”), and Genelife S.A (“Genelife”, head office located at Miguel Laurent 17, Del Valle, Benito Juárez, Mexico City DF, Mexico, Mexico) have entered into a partnership agreement for sales and marketing of our absorbable local hemostat “PuraStat®” in Mexico on February 18th, 2016.

In this agreement, 3DMEU will grant a non-exclusive sales and marketing license to Genelife in Mexico. Once product registration by Genelife is completed, Genelife will then market the product within Mexico through their sales network. Genelife expects that “PuraStat®” will be registered and commercial sale will take place by end of this fiscal year.

Based on this agreement, we have been doing a Mexican market survey with Genelife. Mexico is a key market with a population of over 122 million people, average medical expenditure per capita with 7% growth year on year in 2013^{*1}. Medical market in Mexico is considered high potential growth market because the medical insurance subscription ratio grew from 60% in 2002 to almost 100% currently ^{*1} and the medical and surgical equipment industry is US\$624B in 2013 and is expected to see 6.9% growth year on year by 2020^{*2}. 3-D Matrix group will continue to develop and strengthen sales platform in the Latin America region.

This announcement does not influence the earning forecast of the company at this moment. However, we will make necessary announcements when it is deemed that there is any influence.

Reference:

*1 Source : JETRO, 「Medical Device Market in Mexico」 June, 2013

*2 Source : ProMexico, 「Medical Devices sector」 62:734-764.